CSRNP1

CSRNP1 Full Name

cysteine-serine-rich nuclear protein 1

CSRNP1 Introduction

CSRNP1 (cysteine-serine-rich nuclear protein 1), also known as AXUD1 (AXIN1 upregulated gene 1), is a highly conserved nuclear protein belonging to the CSRNP family, which includes CSRNP1, CSRNP2, and CSRNP3. As a transcription-associated regulatory protein, CSRNP1 is involved in controlling essential cellular processes such as proliferation, differentiation, apoptosis, and stress responses. The major challenge in understanding CSRNP1 is that this nuclear factor does not function as a classical enzyme or receptor target; instead, it acts as a regulatory hub that influences downstream signaling networks. Emerging evidence indicates that CSRNP1 participates in MAPK-related pathways, particularly JNK and p38 signaling, linking cellular stress responses with programmed cell death. Studies have shown that CSRNP1 expression can be induced by inflammatory and stress-related stimuli, including interleukin-2 signaling in immune cells, suggesting its important role in maintaining cellular homeostasis under physiological and pathological conditions.

CSRNP1 has attracted increasing attention because of its dual roles in regulating cell survival and apoptosis depending on the cellular context. Research in ischemia–reperfusion injury demonstrated that CSRNP1 contributes to liver transplantation-associated injury by promoting MAPK-dependent inflammatory and apoptotic responses, while inhibition of CSRNP1 reduced JNK activation and alleviated tissue damage. Mechanistically, CSRNP1 has been associated with mitochondrial dysfunction, reactive oxygen species (ROS) accumulation, and activation of stress-responsive signaling cascades. In hepatocellular carcinoma, CSRNP1 overexpression was reported to impair mitochondrial integrity, increase oxidative stress, and activate the ROS-mediated JNK/p38 MAPK pathway, resulting in enhanced apoptosis. These findings highlight CSRNP1 as a potential regulator connecting oxidative stress, mitochondrial homeostasis, and cancer cell fate, providing new insights for researchers investigating apoptosis-related therapeutic strategies.

Abnormal CSRNP1 expression has been linked to several human diseases, particularly cancer and organ injury. In non-small cell lung cancer (NSCLC), elevated CSRNP1 expression has been associated with poorer disease-free survival, suggesting its potential value as a prognostic biomarker for tumor progression and recurrence. The CSRNP gene family has also been identified as a clinically relevant marker in clear cell renal cell carcinoma, where CSRNP-related expression patterns and DNA methylation changes may influence patient outcomes. Beyond cancer, CSRNP1 has been implicated in ischemic and metabolic disorders, including liver ischemia–reperfusion injury and non-alcoholic fatty liver disease through transcriptomic and bioinformatics analyses. Although CSRNP1 remains an emerging research target, current evidence suggests that its regulation of MAPK signaling, oxidative stress responses, and apoptosis makes it a promising biomarker candidate and a potential therapeutic target for diseases characterized by abnormal cell survival or excessive cellular damage.

Alternate Names for CSRNP1

CSRNP1; cysteine-serine-rich nuclear protein 1; AXUD1; URAX1; TAIP-3; CSRNP-1; FAM130B; cysteine/serine-rich nuclear protein 1; AXIN1 up-regulated 1; axin-1 up-regulated gene 1 protein; TGF-beta induced apoptosis protein 3; TGF-beta-induced apoptosis protein 3;

• 1.Wang Z, et al.; Inhibition of cysteine-serine-rich nuclear protein 1 ameliorates ischemia-reperfusion injury during liver transplantation in an MAPK-dependent manner. Mol Biomed. 2024, 5(1):22.
  2.Xu Z, et al.; Bioinformatics analysis and validation of CSRNP1 as a key prognostic gene in non-small cell lung cancer. Heliyon. 2024, 10(7):e28412.